Becton Dickinson & Co stock faces valuation scrutiny amid recent price weakness and analyst adjustments

The Becton Dickinson & Co stock (ISIN: US0758871091) has declined significantly, trading around $156 on NYSE in USD, prompting debates on whether it's undervalued at a potential 20% discount. Recent earnings beats and FY2026 guidance offer support, but Argus cut its target to $180 while maintaining Buy. US investors eye the pending business separation for margin gains amid healthcare sector shifts.

Becton Dickinson & Co stock has come under pressure, declining about 16% over the past month and 20% in three months on the NYSE in USD. This weakness has sparked investor interest in whether the current levels around $156 represent a buying opportunity in a key medical device player. The company beat recent quarterly estimates with EPS of $2.91 against $2.81 expected and revenue of $5.25 billion versus $5.15 billion forecast, while issuing FY2026 guidance of $12.35 to $12.65 EPS and authorizing a $10 million buyback.

As of: 25.03.2026

Dr. Elena Marquez, Senior Healthcare Analyst: In a sector ripe for consumables-driven medtech leaders, Becton Dickinson & Co's transformation via business separation positions it for predictable cash flows amid US hospital demand resilience.

Recent Earnings Strength Amid Share Price Decline

The Becton Dickinson & Co stock last closed around $156.23 on the NYSE in USD after a period of downward momentum. This follows a 1-year total shareholder return drop of 11.22%, with the stock hitting a 52-week low near $127.62 and high of $187.35. Investors note the contrast with solid fundamentals: last quarter's revenue hit $5 billion, beating by $104 million, and EPS exceeded estimates by $0.09.

Management's FY2026 EPS guidance of $12.35-$12.65 signals confidence in recovery, supported by a new $10 million share buyback authorization. Trading volume has risen with price action in recent sessions, a positive technical sign as the stock gained 0.92% in one session to $185.32 before recent pullbacks—though levels vary across reports, underscoring volatility on NYSE in USD. The horizontal trend suggests potential for movement between $165 and $207 over three months.

Analyst Views Highlight Undervaluation Debate

Analysts see the Becton Dickinson & Co stock as potentially undervalued, with a narrative fair value of $197.15 against the recent close of $156.23 on NYSE in USD—a 20.8% discount. This view hinges on the pending separation of Biosciences and Diagnostic Solutions businesses, aiming to create a pure-play medtech firm with over 90% revenue from consumables for higher margins and cash flow predictability.

Argus Research adjusted its price target downward to $180 from $230 on March 23, 2026, but kept a Buy rating, reflecting caution yet optimism. Support levels cluster around $175.34 and $169.54, with resistance at $185.84 and higher. Buy signals from moving averages and MACD support a positive forecast, though breakdowns could trigger sells.

Business Separation as Key Catalyst

Becton Dickinson & Co operates in Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences segments, supplying hospitals, labs, and pharma firms globally. The planned spin-off of Biosciences and Diagnostics aims to streamline into a consumables-focused medtech leader. This shift promises margin expansion and EPS growth via aggressive buybacks post-separation.

Recurring revenue from disposables provides stability in healthcare, where procedure volumes drive demand. US hospitals, facing staffing pressures but steady elective procedures, form a core market. The transformation addresses investor calls for focus amid diversified exposure.

US Investor Relevance in Medtech Landscape

For US investors, Becton Dickinson & Co stock offers exposure to resilient medtech demand, with domestic hospitals prioritizing essentials like syringes and infusion systems. Recent earnings beats underscore execution amid reimbursement stability under Medicare. The buyback and guidance signal capital return focus, attractive in a high-interest environment.

Compared to peers, the stock's discount to fair value appeals for dividend seekers—yielding steadily with quarterly payouts like $1.04. Portfolio diversification into defensive healthcare benefits from aging demographics and chronic disease trends boosting device usage.

Sector Dynamics and Competitive Position

In medtech, Becton Dickinson & Co competes via scale in vascular access and diagnostics. Consumables dominance (>90% post-spin) mirrors peers like Intuitive Surgical but with broader reach. Pipeline in connected care aligns with telehealth growth, while BioPharma supports drug delivery innovation.

Regional mix favors US stability over emerging market volatility. Tariff risks loom for imports, but domestic manufacturing mitigates. Execution on separation will dictate multiple expansion.

Risks and Open Questions Ahead

Key risks include delays in the business separation, potentially impacting margins more than expected. Trade tariffs could pressure costs, while execution risks in integration post-spin loom. Recent analyst target cuts reflect near-term caution despite Buy ratings.

Support breaks below $169 could accelerate declines, with volume key to watch. Broader healthcare policy shifts, like drug pricing reforms, indirectly affect device reimbursement. Investors must weigh undervaluation narrative against these uncertainties.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.